Do you consider MSI testing for nonserous ovarian cancer?  

I do, but with the understanding that PD1/PDL1 expression, MSI/MMR is less well documented than in high grade serous cancers. Meagher et al has a nice article in Gyn Oncol 2018 looking at molecular profiling in 333 mucinous lesions. Common mutations noted were KRAS (60%), TP53 (38%), and HER2 in up ...